Clinical Trial Update: A Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202) [Phase 3]

View source ↗

Summary

This document reports the completion and long-term results of the ambrisentan extension study in patients with pulmonary arterial hypertension, following earlie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• LETAIRIS (ambrisentan)

Snippet

Sponsor: Gilead Sciences | Conditions: Pulmonary Arterial Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2013-01-15